在5年内,在代谢功能障碍相关的性肝病中肝硬化症的显著变化:使用受控减弱参数的社区研究
Marta Cervera1,2,3, Martina Pérez-Guasch1,2, Marta Carol3
1Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
United European gastroenterology journal
|October 8, 2025
概括
肝脏脂肪含量在五年内在一般人群中大幅波动,许多病例得到解决,新的病例正在发展. 与代谢功能障碍相关的脂肪性肝病 (MASLD) 的这些动态变化对于流行病学研究至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 流行病学 流行病学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一种普遍存在的疾病,与肝硬化和肝癌等严重健康结果有关.
- 肝脏脂肪的积累是MASLD进展的核心,但在一般人群中肝脏脂肪的纵向变化仍然不太了解.
研究的目的:
- 在一般人口队列中,研究五年内肝脏脂肪含量的动态变化.
- 在没有具体干预的情况下,以确定肥胖症解决和发展的频率.
主要方法:
- 一项纵向研究在五年内跟踪了195名随机选择的个体,通过暂时弹性学评估肝脂肪,使用受控减弱参数 (CAP).
- 肥胖症的解消被定义为>10%的CAP降低到<275dB/m,发展为>10%的CAP增加到≥275dB/m.
- 在一个单独的横截面研究 (n=101) 中评估了CAP变异性,显示平均变异性为9.9%.
主要成果:
- 肝脏脂肪的显著变化被观察到;34%的参与者与基线肥胖症经历了解决 (CAP从300降至237dB/m,p<0.001).
- 肥胖症的解决与体重减轻和肝酶 (透氨酶,胺转移酶) 的降低相关.
- 相反,在没有基线肥胖症的参与者中,有29%的人患上了肥胖症,肝硬度增加 (≥8kPa) 与持续的肥胖症有关,而不是解决.
结论:
- 肝脏脂肪含量在五年内在一般人群中表现出相当大的活力.
- 这些波动凸显了MASLD的动态性质,是流行病学研究和临床管理的重要考虑因素.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
212
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
212
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
253
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
253
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
212
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
212